CLARA DAY ON OPERATIONS RESEARCH IN CANCER TREATMENT & OPERATION MANAGEMENT

Size: px
Start display at page:

Download "CLARA DAY ON OPERATIONS RESEARCH IN CANCER TREATMENT & OPERATION MANAGEMENT"

Transcription

1 CLARA DAY ON OPERATIONS RESEARCH IN CANCER TREATMENT & OPERATION MANAGEMENT November 17, 2010 SPEEDING UP PROGRESS

2 Seven Cancer Research Networks within France Cancer in France Incidence 315,000 / year Mortality 150,000 / year To facilitate and coordinate Cancer research, in particular Translational Research. Coordination by French National Cancer Institute (INCa). Sous l'égide de la Fondation Bullukian P 2

3 CLARA: research network organization European and international dimension P 3

4 CLARA goals Rapid transfer of research to patients Economic development of oncology research Translational Cancer Research Sous l'égide de la Fondation Bullukian P 4

5 CLARA major partners with international leadership position CEA-Leti : Atomic Energy Commission Electronic and Information Technology Laboratory CERN: European Organization for Nuclear Research CRMN: European Center for High Field NMR ELI : European Lymphoma Institute IARC: International Agency for Research on Cancer ELuI: European Lung Institute PARCC-ARA: Support Platform for Clinical Research in Oncology in the inter-region Rhône- Alpes Auvergne WSN: World Sarcoma Network LYON CRMN ELI IARC PARCC WSN GENEVA CERN GRENOBLE CEA-Leti ELuI P 5

6 CLARA major Cancer pathologies with international leadership position 1 st order Lymphoma ELI Pr Coiffier Pr Salles Sarcoma WSN Pr Blay Lung LCEH Pr Brambilla 2 nd order Glioblastoma Hepatocarcinoma Pr Honnorat Pr Berger Pr Trepo, Pr Zoulim, Pr Merle P 6

7 CLARA s whole spectrum of competitive platforms Clinical research Hadrontherapy Bio therapies Cancer prevention Cancer epidemiology Patient bed site Metabolomics Proteomics Genomics - Epigenomics Lab bench Imaging facilities Experimental cancer models Bio informatics Nanotechnologies Pharmacogenomics 50M investment P 7

8 European Observatory of Cancer France Data about Europe P 8

9 CLARA Strengths and Key Features Unique integrated research network focused on oncology in Rhône-Alpes-Auvergne Brings out, evaluates and assists R&D projects involving interdisciplinary experts at the academic, clinical and private companies level Flexible, reactive and significant funding thanks to the support of INCa, local authorities, and European funds making possible both the CLARA Proof of concept programme and CLARA core projects Neutral and independent interface towards private investors and research organisations Sous l'égide de la Fondation Bullukian P 9

10 CLARA auto-analysis STRONG POINTS Significant contribution of CLARA researchers to high-impact journals Five IBiSA national certifications have been granted to CLARA platforms and three major biological resources centres have been certificated CLARA Portfolio of 25 Proof of concept projects ( 32M) based on academic-clinical-industrial cooperation Initiation of first class projects for enhanced visibility and attractiveness of research CLARA mobilises diversified funding resources P 10

11 INCa-funded projects INCa 2009 Activity Report Sous l'égide de la Fondation Bullukian P 11

12 Synopsis of bibliometric analysis Quantitative evolution of publications 140% Progression index (2005 as 100%) 130% 120% 110% World France CLARA 100% year Sous l'égide de la Fondation Bullukian P 12

13 Synopsis of bibliometric analysis Cancéropôles contribution to international visibility Sous l'égide de la Fondation Bullukian P 13

14 CLARA s Proof of Concept programme Growth of CLARA projects portfolio 30 Number of projects Completed with Proof of Concept Completed Ongoing Year Sous l'égide de la Fondation Bullukian P 14

15 CLARA PoC economical impact The projects have generated a variety of economic spillovers. 18 start-ups and SMEs have invested 22 M (versus 10M by CLARA), and 11 companies have reached significant growth milestones : 5 start-ups have been created: idd Biotech, Ecrin Therapeutics, Fluoptics, Netris Pharma and Synthelis, 1 foreign company subsidiary establishment in the region : OncoTherapy Science from Japan, 5 companies raised capital (> 40M) : EDAP TMS, EndoControl Medical, ERYtech Pharma, ImmunID Technologies and Nanobiotix, 4 companies are listed on the stock exchange or trade sale: EDAP TMS, Genome Express, Innate Pharma (IPO) and OPi. Sous l'égide de la Fondation Bullukian P 15

16 CLARA scientific events CLARA organised event co-organised with another Cancéropôle Sous l'égide de la Fondation Bullukian P 16

17 Priorities for Further mobilise its network on two priorities: identification and assistance to projects of academic clinical industrial partnerships in the field of cancer Develop synergies with key regional partners and abroad in the frame of project detection, evaluation, maturing and funding Reinforce communication on its strategy, projects and results, especially on the Cancéropôle CLARA s Proof of Concept programme Gain further financial support from INCa, regional authorities, French programmes and European funds to support ambitious projects P 17

18 Work plan Transverse actions Technological platforms and biological resources centres Support to Clinical Research Proof of concept Axis I: Tumour escape, cell plasticity and targeted therapy Priority axes Axis II: Infections and Cancer Axis III: Nanotechnology, imaging and cancer Axis A: Evaluation, risk perception and cancer prevention Emerging axes Axis B: Environment, nutrition and cancer Axis C: Hadrontherapy and cancer P 18

19 CLARA Ambition for 2014 Expand the CLARA Proof of Concept programme in oncology to other European regions A significant move within its projects from pre-clinical studies to clinical trials An increased participation of CLARA teams to European programmes and ambitious initiatives An acceleration of company creations, development and arrival in the region A broad-spectrum network of experts providing services to oncology research and patients A clear visibility of CLARA s research within the nation and elsewhere in Europe P 19

20 Support to Clinical Research Clinical PARCC-ARA platform PHRC cancer Data management Information Training Support to CLARA s major cancer pathologies European Lymphoma Institute (ELI) World Sarcoma Network (WSN) European Lung Institute (ELuI) In support of Measure 4, Cancer Plan II to stimulate clinical research P 20

21 Project of Evaluation, Risk Perception and Cancer Prevention Links Prevention Primary prevention Identification of risk factors Patients perception of risks Screening Evaluation of screening programmes Determinants of participation to screening programmes Targeted interventions in non-participative population Axis B Axis III Therapeutic management Collective / individual decision-making Quantitative analysis Qualitative analysis Therapeutic management optimisation Homecare Patients education programmes In support of Measure 2, Cancer Plan II to understand through research and reduce inequalities in relation to cancer With support of the interregional Regional Resources Centre for Information, Prevention and Education about Cancers (Hygée centre, St-Etienne) P 21

22 Project of Evaluation, Risk Perception and Cancer Prevention Patients involvement Health inequalities Prevention Education of intermediaries for cancer mass screening in nonprivileged areas Reasons for either participating or not to cancer mass screening Health inequalities for breast and colon cancer screening Therapeutic management Develop a multidisciplinary approach Study the role and consequences of inequalities rather than their description Participate to the development of methods to evaluate interventions to reduce health inequalities Economic study on adherence to clinical practice in sarcoma Determinants of therapeutic management for patients with broncho-pulmonar cancer Evaluation of therapeutic management of hospital vs. home chemotherapy Optimum mapping of various organisational methods according to geographical, epidemiological and demographic situations P 22

23 Thanks to our partners P 23

AERES report on the canceropole

AERES report on the canceropole Section des Unités de recherche AERES report on the canceropole Canceropole CLARA From the Institut du Cancer February 2011 Section des Unités de recherche AERES report on the canceropole Canceropole CLARA

More information

ELEFTHO : Supporting Business Incubators & technology parks.

ELEFTHO : Supporting Business Incubators & technology parks. ELEFTHO : Supporting Business Incubators & technology parks. Region of Central Macedonia Task Page 1 of 14 Contents Description of policy... 3 Name of the policy... 3 Responsible body... 3 Implementation

More information

20 11 PROGRESS REPORT

20 11 PROGRESS REPORT 2011 PROGRESS REPORT Contents Editorial p.3 2011 Landmarks p.4 Key figures p.4 Outstanding events p.4 Cancéropôle CLARA : recognized assets and renewed confidence p.6 for the 2011-2014 period AERES: a

More information

Career Opportunities within the French Alliance for Life and Health Sciences

Career Opportunities within the French Alliance for Life and Health Sciences 1 Career Opportunities within the French Alliance for Life and Health Sciences Mireille Guyader, PhD Director, Inserm-USA Office INSERM KEY FIGURES (Year 2013) Budget: 970 M (~ $1.2 Billion) Human resources:

More information

PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009

PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 Christelle Dagoneau, PhD Business Development Director Company Profile Protein expert incorporated in 2000

More information

Cancer plan 2009 2013

Cancer plan 2009 2013 Cancer plan 2009 2013 Launched on 2 November 2009 in Marseille Introduction 3 The Cancer Plan 2009-2013 was inspired by the report submitted to the French President by Prof. Jean-Pierre Grünfeld in February

More information

No. prev. doc.: 8770/08 SAN 64 Subject: EMPLOYMENT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS COUNCIL MEETING ON 9 AND 10 JUNE 2008

No. prev. doc.: 8770/08 SAN 64 Subject: EMPLOYMENT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS COUNCIL MEETING ON 9 AND 10 JUNE 2008 COUNCIL OF THE EUROPEAN UNION Brussels, 22 May 2008 9636/08 SAN 87 NOTE from: Committee of Permanent Representatives (Part 1) to: Council No. prev. doc.: 8770/08 SAN 64 Subject: EMPLOYMENT, SOCIAL POLICY,

More information

Recruiting Emerging Leaders in Oncology

Recruiting Emerging Leaders in Oncology ARC Foundation Call for proposals 2016 Recruiting Emerging Leaders in Oncology Letter of intent submission deadline: July 8 th, 2015 1. Background and Objectives To heighten France's competitiveness and

More information

Centre Jean Perrin. Centre de Lutte contre le Cancer d'auvergne CANCER CARE NETWORK

Centre Jean Perrin. Centre de Lutte contre le Cancer d'auvergne CANCER CARE NETWORK Centre Jean Perrin Centre de Lutte contre le Cancer d'auvergne Clermont-Ferrand - France - CANCER CARE NETWORK Mohun R K (Kailash) BAHADOOR Réseau Oncauvergne Centre Jean Perrin Clermont Ferrand WHY CANCER

More information

Oncoxx Biotech. Saverio Alberti. Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis

Oncoxx Biotech. Saverio Alberti. Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis Oncoxx Biotech Saverio Alberti Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis INTRODUCTION Oncoxx Biotech S.r.l. is a Cancer Biotech Company as partnership between Chieti University

More information

2 nd PROCART Forum. October 9th, 2012

2 nd PROCART Forum. October 9th, 2012 2 nd PROCART Forum October 9th, 2012 The main investments in cancer research 2012 research Spending 120 M Including INCa, Aviesan cancer, Ministry of Health cancer biology, cancer sciences, genomics Activities

More information

Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles

Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles ITMO Neurosciences, sciences cognitives, neurologie, psychiatrie Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles ITMO Technologie pour la santé 1 NEUROSCIENCE MEDICAL CHALLENGES

More information

HCERES report on research unit:

HCERES report on research unit: Research units HCERES report on research unit: Actions for oncogenesis understanding and Target Identification in ONcology ACTION Under the supervision of the following institutions and research bodies:

More information

Life Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com

Life Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com Life Science Sector Opportunities Northern Ireland investni.com Introduction Clinical trials commonly refer to testing the effectiveness of experimental drugs and are typically categorised into four phases;

More information

ARC Foundation Call for Projects 2015 CANC AIR Prevention of cancers linked to exposure to air pollutants

ARC Foundation Call for Projects 2015 CANC AIR Prevention of cancers linked to exposure to air pollutants ARC Foundation Call for Projects 2015 CANC AIR Prevention of cancers linked to exposure to air pollutants Notice of call for projects 1- Background In 2012, it is estimated that 355,000 new cases of cancer

More information

There must be an appropriate administrative structure for each residency program.

There must be an appropriate administrative structure for each residency program. Specific Standards of Accreditation for Residency Programs in Radiation Oncology 2015 VERSION 3.0 INTRODUCTION The purpose of this document is to provide program directors and surveyors with an interpretation

More information

THE STRENGTH OF THE ONCOPOLE, a radically new pooling of expertise

THE STRENGTH OF THE ONCOPOLE, a radically new pooling of expertise TRAINING + RESEARCH + HEALTHCARE + INDUSTRY : THIS IS THE ONCOPOLE. THE STRENGTH OF THE ONCOPOLE, a radically new pooling of expertise The Oncopole is the only site in Europe that brings together both

More information

Secondary Uses of Data for Comparative Effectiveness Research

Secondary Uses of Data for Comparative Effectiveness Research Secondary Uses of Data for Comparative Effectiveness Research Paul Wallace MD Director, Center for Comparative Effectiveness Research The Lewin Group Paul.Wallace@lewin.com Disclosure/Perspectives Training:

More information

Public Health and. Interdisciplinary Context. Birgitta Edlund RNT

Public Health and. Interdisciplinary Context. Birgitta Edlund RNT 1 Public Health and Caring Science Nursing Education in an Extended Interdisciplinary Context Birgitta Edlund RNT Associate Professor 2 Uppsala 3 University Main Building 4 Uppsala University Research

More information

DWI Case Study - QIBA PDF- MRI Technical Committee. What is IMI?

DWI Case Study - QIBA PDF- MRI Technical Committee. What is IMI? DWI Case Study - QIBA PDF- MRI Technical Committee QIBA Annual Meeting May 21, 2014 What is IMI? The Innovative Medicines Initiative (IMI) is the world s largest biomedical /healthcare public-private initiative

More information

2014 Onxeo Review and 2015 Perspectives

2014 Onxeo Review and 2015 Perspectives 2014 Onxeo Review and 2015 Perspectives 2014 Consolidated Financial Results - Successful strategic merger and acquisition of Danish company Topotarget giving birth to Onxeo - Products major achievements:.

More information

2019 Healthcare That Works for All

2019 Healthcare That Works for All 2019 Healthcare That Works for All This paper is one of a series describing what a decade of successful change in healthcare could look like in 2019. Each paper focuses on one aspect of healthcare. To

More information

Chapter 6. Financing of innovative entrepreneurs

Chapter 6. Financing of innovative entrepreneurs Chapter 6. Financing of innovative entrepreneurs Ukraine has entrepreneurial talent and a relatively strong risk-taking attitude. These are major ingredients for any policy intervention seeking to promote

More information

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions

More information

Clinical research at AP-HP (Paris Public Hospitals)

Clinical research at AP-HP (Paris Public Hospitals) Clinical research at AP-HP (Paris Public Hospitals) Clinical research at AP-HP A strict regulatory framework (biomedical research) a sponsor in the sense of the French Public Health Code opinion of a Committee

More information

ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April 2015 13:10 14:20 Room C

ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April 2015 13:10 14:20 Room C ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC Thursday 16th April 2015 13:10 14:20 Room C 1 Contents Programme.... 2 Welcome message.... 3 Faculty biographies.... 4 Symposium

More information

Il ruolo dell Advisory Group for «Health, Wellbeing and Demographic Change» in Horizon 2020

Il ruolo dell Advisory Group for «Health, Wellbeing and Demographic Change» in Horizon 2020 Il ruolo dell Advisory Group for «Health, Wellbeing and Demographic Change» in Horizon 2020 Lucia Monaco Horizon 2020 Advisory Group, Societal Challenges 1: Health, Demographic Change and Wellbeing Seminario:

More information

The Department of Public Health Sciences

The Department of Public Health Sciences The Department of Public Health Sciences Who we are at the U.Va. School of Medicine Committed to improving population health and clinical care The Department of Public Health Sciences, established in 1995,

More information

Journée des Industriels du Réseau TRIGGERSEP

Journée des Industriels du Réseau TRIGGERSEP Journée des Industriels du Réseau TRIGGERSEP Djillali ANNANE Hôpital Raymond Poincaré (AP-HP) Lab Cell Death Inflamation & Infection UMR1173 UVSQ/INSERM Mercredi 3 juin 2015 Institut Pasteur Paris Expertise:

More information

Unlock Your Global Business Potential: Supporting Life Sciences in the UK

Unlock Your Global Business Potential: Supporting Life Sciences in the UK Unlock Your Global Business Potential: Supporting Life Sciences in the UK Dr Mark Treherne, Chief Executive, Life Science Investment Organisation Health Research Authority 31 st March, 2014 THE UK HAS

More information

Big data in cancer research : DNA sequencing and personalised medicine

Big data in cancer research : DNA sequencing and personalised medicine Big in cancer research : DNA sequencing and personalised medicine Philippe Hupé Conférence BIGDATA 04/04/2013 1 - Titre de la présentation - nom du département émetteur et/ ou rédacteur - 00/00/2005 Deciphering

More information

Institut Curie Co-fund PhD program IC-3i-PhD

Institut Curie Co-fund PhD program IC-3i-PhD Institut Curie Co-fund PhD program IC-3i-PhD Institut Curie Hospital group Research Center Private foundation, created in 1909 accepting public donations A leading player in the fight against cancer Institutional

More information

Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Paediatric Cancer Treatment

Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Paediatric Cancer Treatment Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Paediatric Cancer Treatment Reference: NHS England xxx/x/x 1 Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy)

More information

14. INTENSIVE CHEMOTHERAPY TREATMENT OF GERM CELL TUMOURS

14. INTENSIVE CHEMOTHERAPY TREATMENT OF GERM CELL TUMOURS Guidelines to be followed by centres, services and units in order to be designated as Reference Centres, Services and Units of the National Health System. as agreed by the Interterritorial Board 14. INTENSIVE

More information

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

More information

THE LINCOLN INSTITUTE OF HEALTH

THE LINCOLN INSTITUTE OF HEALTH THE LINCOLN INSTITUTE OF HEALTH Background The Chair in the Care of the Older Person will be part of the new Lincoln Institute of Health, a cross disciplinary research collaboration linking schools, colleges

More information

Increasing Innovation in R&D - Seizing early stage external growth opportunities

Increasing Innovation in R&D - Seizing early stage external growth opportunities Increasing Innovation in R&D - Seizing early stage external growth opportunities Paul R. Eynott, PhD sanofi-aventis, US paul.eynott@sanofi-aventis.com -1- Sommaire -2- CHRISTOPHER A. VIEHBACHER Chief Executive

More information

How to measure excellence: the case of the Swiss NCCRs Stefan Bachmann, SNSF

How to measure excellence: the case of the Swiss NCCRs Stefan Bachmann, SNSF How to measure excellence: the case of the Swiss NCCRs Stefan Bachmann, SNSF Contents 1. The SNSF in summary 2. National Centres of Competence in Research (NCCR) 3. Evaluation, progress reporting and output

More information

Lyon, 13 14 May 2015 Auditorium

Lyon, 13 14 May 2015 Auditorium Fifty-seventh Session 22/04/2015 Lyon, 13 14 May 2015 Auditorium ADMISSION OF A NEW PARTICIPATING STATE Morocco 1. The Director has the honour to inform the Governing Council that the Government of the

More information

Accelerate the time to international market for innovative companies and enhance connections within the local health ecosystem

Accelerate the time to international market for innovative companies and enhance connections within the local health ecosystem Accelerate the time to international market for innovative companies and enhance connections within the local health ecosystem Medic@lps film : Grenoble/Isére Health ecosystem http://www.medicalps.eu Contents

More information

THE RESEARCH INFRASTRUCTURES IN FP7

THE RESEARCH INFRASTRUCTURES IN FP7 29 October 2004 Working Document on THE RESEARCH INFRASTRUCTURES IN FP7 Introduction In the Commission s communication on the financial perspectives of the European Union for the period 2007-2013 1, the

More information

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The

More information

Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development

Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development Strasbourg, 11 March 2008 Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development Strasbourg, France, March 11, 2008 Transgene (Euronext Paris: FR0005175080) announces

More information

1) SCOPE OF THE PROGRAM

1) SCOPE OF THE PROGRAM CALL FOR PROJECTS 2015/16 CANADA/GERMANY JOINT PROGRAM DEADLINE: 15 TH JANUARY 2016 1) SCOPE OF THE PROGRAM The main goal of the Canada/Germany joint program is to strengthen research in Canada and Germany

More information

Global Monoclonal Antibodies Pipeline Insight 2015

Global Monoclonal Antibodies Pipeline Insight 2015 Brochure More information from http://www.researchandmarkets.com/reports/3113388/ Global Monoclonal Antibodies Pipeline Insight 2015 Description: Ever since the Nobel Prize was bestowed on the person who

More information

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015 Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future

More information

MATWIN Programme 2015 Support for the Proof of Concept Project Application Form

MATWIN Programme 2015 Support for the Proof of Concept Project Application Form MATWIN Programme 2015 Support for the Proof of Concept Project Application Form For internal use only: Cancéropôle partner: Date of receipt: File number: MATWIN is a nationwide programme that identifies

More information

Draft NIEHS Strategic Plan. Mission, Vision, Strategic Pillars, Strategic Goals. Draft Mission Statement

Draft NIEHS Strategic Plan. Mission, Vision, Strategic Pillars, Strategic Goals. Draft Mission Statement Draft NIEHS Strategic Plan Mission, Vision, Strategic Pillars, Strategic Goals Draft Mission Statement The mission of the National Institute of Environmental Health Sciences is to discover how the environment

More information

Master of Science in Biomedical Sciences

Master of Science in Biomedical Sciences Master of Science in Biomedical Sciences Faculty of Medicine Good health is our greatest treasure. Understanding the human body, healthy and diseased, is the stepping stone to finding tools to improving

More information

The National Institute of Genomic Medicine (INMEGEN) was

The National Institute of Genomic Medicine (INMEGEN) was Genome is...... the complete set of genetic information contained within all of the chromosomes of an organism. It defines the particular phenotype of an individual. What is Genomics? The study of the

More information

Subdomain Weight (%)

Subdomain Weight (%) CLINICAL NURSE LEADER (CNL ) CERTIFICATION EXAM BLUEPRINT SUBDOMAIN WEIGHTS (Effective June 2014) Subdomain Weight (%) Nursing Leadership Horizontal Leadership 7 Interdisciplinary Communication and Collaboration

More information

Call for Demonstrator Projects

Call for Demonstrator Projects Association of the British Pharmaceutical Industry 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT t +44 (0)870 890 4333 www.abpi.org.uk Call for Demonstrator Projects ABPI Big Data Demonstrators

More information

Chirurgie des métastases cérébrales. Dr Mark Dexter Head, Department of Neurosurgery The Westmead Hospitals

Chirurgie des métastases cérébrales. Dr Mark Dexter Head, Department of Neurosurgery The Westmead Hospitals Chirurgie des métastases cérébrales Dr Mark Dexter Head, Department of Neurosurgery The Westmead Hospitals The Westmead patient population THE INCONVENIENT TRUTHS Cerebral metastases occur in 10 16 % of

More information

Monitoring and assessment tools 24 April 2014

Monitoring and assessment tools 24 April 2014 www.pwc.com Monitoring and assessment tools 24 April 2014 Agenda Section Page 1 The PACA Region in a nutshell 1 2 The Regional Innovation Observatory : the origins 4 The Regional Innovation Observatory

More information

Degree Level Expectations, Learning Outcomes, Indicators of Achievement and the Program Requirements that Support the Learning Outcomes

Degree Level Expectations, Learning Outcomes, Indicators of Achievement and the Program Requirements that Support the Learning Outcomes Department/Academic Unit: Pathology and Molecular Medicine Degree Program: PhD Degree Level Expectations, Learning Outcomes, Indicators of Achievement and the Program Requirements that Support the Learning

More information

Oncoxx Biotech. Saverio Alberti. Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis

Oncoxx Biotech. Saverio Alberti. Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis Oncoxx Biotech Saverio Alberti Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis INTRODUCTION Oncoxx S.r.l. is a Cancer Biotech Company as partnership between Chieti University

More information

Report to UCLH Board Bryan Williams MD FRCP FESC FAHA

Report to UCLH Board Bryan Williams MD FRCP FESC FAHA NIHR University College London Hospitals Report to UCLH Board Bryan Williams MD FRCP FESC FAHA Professor of Medicine and BRC Director 18/03/2013 The NIHR UCLH BRC Renewed funding circa 100M for 5 years

More information

Nuevas tecnologías basadas en biomarcadores para oncología

Nuevas tecnologías basadas en biomarcadores para oncología Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS

More information

Next Generation Sequencing Informatics Markets

Next Generation Sequencing Informatics Markets Next Generation Sequencing Informatics Markets Greg Caressi SVP Healthcare & Life Sciences November, 2014 Personalization, Communication, Decentralization, Collaboration From... One Size Fits All APPROACH...To

More information

Key Findings. Use this report to... The Top 10 Contract Research Organizations

Key Findings. Use this report to... The Top 10 Contract Research Organizations Key Findings The global CRO industry valued $18bn in 2008, an increase of 14% over 2007. The CRO market will grow at an annual rate of 14% over the 2009 13 period. Quintiles leads the global CRO market

More information

Kentucky Lung Cancer Research Program. 2010 Strategic Plan Update

Kentucky Lung Cancer Research Program. 2010 Strategic Plan Update Kentucky Lung Cancer Research Program 2010 Strategic Plan Update Approved by the KLCR Program Governance Board August 12, 2009 KLCR Program Strategic Plan Table of Contents Introduction... 3 GOAL 1: Investigator-Initiated

More information

CURRICULUM VITAE. 1231 Conches (Swtzerland) 0041-76-316.10.38 (personal assistant) Private phone number 0041-22-830.15.45

CURRICULUM VITAE. 1231 Conches (Swtzerland) 0041-76-316.10.38 (personal assistant) Private phone number 0041-22-830.15.45 1Curriculum vitae F.A. Waldvogel, M.D. 1 CURRICULUM VITAE WALDVOGEL Francis A. Origin Geneva (Switzerland) Date of birth October 19, 1938 Languages French, German, English (fluent) Italian (good understanding)

More information

Call for Proposals 2015 Open Science - Training and Higher Education TERMS OF REFERENCE 21 JANUARY 2015

Call for Proposals 2015 Open Science - Training and Higher Education TERMS OF REFERENCE 21 JANUARY 2015 AGROPOLIS FONDATION Call for Proposals 2015 Open Science - Training and Higher Education [Ref. CfP 2015-01] TERMS OF REFERENCE 21 JANUARY 2015 Introduction Agropolis Fondation s mission is to promote and

More information

ECRIN IA WP4 Breakout session: structuring a European rare disesase clinical research network ECRIN Annual meeting 15-17 may 2013 Warsaw

ECRIN IA WP4 Breakout session: structuring a European rare disesase clinical research network ECRIN Annual meeting 15-17 may 2013 Warsaw ECRIN IA WP4 Breakout session: structuring a European rare disesase clinical research network ECRIN Annual meeting 15-17 may 2013 Warsaw OrphanDev s experience in supporting Clinical Trials for rare diseases

More information

Section 4.1 Working together to deliver on Europe 2020

Section 4.1 Working together to deliver on Europe 2020 Response to the European Commission Green Paper From Challenges to Opportunities: Towards a Common Strategic Framework for EU Research and Innovation funding ECCO, the European CanCer Organisation, exists

More information

Editorial. Yves Levy, Executive Director

Editorial. Yves Levy, Executive Director Editorial Yves Levy, Executive Director I am delighted to announce the creation of a new research centre: the Vaccine Research Institute (VRI). The VRI addresses the unprecedented challenge of developing

More information

M.Sc. in Nano Technology with specialisation in Nano Biotechnology

M.Sc. in Nano Technology with specialisation in Nano Biotechnology M.Sc. in Nano Technology with specialisation in Nano Biotechnology Nanotechnology is all about designing, fabricating and controlling materials, components and machinery with dimensions on the nanoscale,

More information

Nanomedicine in Horizon 2020

Nanomedicine in Horizon 2020 Nanomedicine in Horizon 2020 Heico FRIMA Programme Officer European Commission Directorate-General for Research & Directorate D: Key Enabling Technologies heico.frima@ec.europa.eu ETPN Annual Event 2014

More information

HCERES report on research unit: Under the supervision of the following institutions and research bodies: Targeted Therapies in Oncology

HCERES report on research unit: Under the supervision of the following institutions and research bodies: Targeted Therapies in Oncology Research units HCERES report on research unit: Targeted Therapies in Oncology Under the supervision of the following institutions and research bodies: Université Claude Bernard Lyon 1 - UCB Université

More information

The NIH Roadmap: Re-Engineering the Clinical Research Enterprise

The NIH Roadmap: Re-Engineering the Clinical Research Enterprise NIH BACKGROUNDER National Institutes of Health The NIH Roadmap: Re-Engineering the Clinical Research Enterprise Clinical research is the linchpin of the nation s biomedical research enterprise. Before

More information

EVT Execute & EVT Innovate World-class drug discovery

EVT Execute & EVT Innovate World-class drug discovery EVT Execute & EVT Innovate World-class drug discovery Evotec AG, First Quarter Report 2015, 12 May 2015 Forward-looking statements Information set forth in this presentation contains forward-looking statements,

More information

ONCOLOGY DERMATOLOGY A-DERMA AVÈNE DUCRAY ELANCYL GALÉNIC KLORANE RENÉ FURTERER

ONCOLOGY DERMATOLOGY A-DERMA AVÈNE DUCRAY ELANCYL GALÉNIC KLORANE RENÉ FURTERER Pierre Fabre is the 3rd largest French pharmaceutical group. In 2013, its sales reached 2.008 Billion, with international revenues accounting for 56%. Founded and its headquarters still based in the South-west

More information

Company Profile // May 2012

Company Profile // May 2012 Company Profile // May 2012 1 Disclaimer This presentation has been prepared for the group of companies held by Clal Biotechnology Industries Ltd. (CBI or the Group ) and is provided to you solely for

More information

MSD Information Technology Global Innovation Center. Digitization and Health Information Transparency

MSD Information Technology Global Innovation Center. Digitization and Health Information Transparency MSD Information Technology Global Innovation Center Digitization and Health Information Transparency 10 February 2014 1 We are seeking energetic, forward thinking graduates to join our Information Technology

More information

National Professional Development Framework for Cancer Nursing in New Zealand

National Professional Development Framework for Cancer Nursing in New Zealand National Professional Development Framework for Cancer Nursing in New Zealand Adapted from: National Cancer Education Project (EdCan). 2008. National Education Framework: Cancer nursing A national professional

More information

Masters of Science in Clinical Research (MSCR) Curriculum. Goal/Objective of the MSCR

Masters of Science in Clinical Research (MSCR) Curriculum. Goal/Objective of the MSCR Masters of Science in Clinical (MSCR) Curriculum Goal/Objective of the MSCR The MSCR program is an interdisciplinary research degree program housed within the Department of Epidemiology in the School of

More information

PROTON THERAPY. Proton Therapy World Market Report Edition 2015 WORLD MARKET REPORT EDITION 2015. MEDraysintell. 2015 www.medraysintell.

PROTON THERAPY. Proton Therapy World Market Report Edition 2015 WORLD MARKET REPORT EDITION 2015. MEDraysintell. 2015 www.medraysintell. Proton Therapy World Market Report Edition 2015 PROTON THERAPY WORLD MARKET REPORT EDITION 2015 A report written by Paul-Emmanuel Goethals & Richard Zimmermann Page 1/7 www.medraysintell.com Proton Therapy

More information

Bachelor of Nursing Programme

Bachelor of Nursing Programme Bachelor of Nursing Programme 1 Bachelor of Nursing Programme This is a four-year full-time undergraduate nursing degree programme. Graduates of this programme will be prepared for registration as General

More information

The European Innovation Council A New Framework for EU Innovation Policy

The European Innovation Council A New Framework for EU Innovation Policy The European Innovation Council A New Framework for EU Innovation Policy EARTO recommendations to the European Commission to initiate further discussion 9 October 2015 Introduction: EIC as a Key Action

More information

Call 2014: High throughput screening of therapeutic molecules and rare diseases

Call 2014: High throughput screening of therapeutic molecules and rare diseases Call 2014: High throughput screening of therapeutic molecules and rare diseases The second call High throughput screening of therapeutic molecules and rare diseases launched by the French Foundation for

More information

Positions Available in SINAPSE INSTITUTE in Singapore

Positions Available in SINAPSE INSTITUTE in Singapore Positions Available in SINAPSE INSTITUTE in Singapore The SINAPSE Institute (www.sinapseinstitute.org), under the direction of Prof. Nitish Thakor (www.jhu.edu/nthakor), is a newly launched research institute

More information

Cachexia and Nutrition in Advanced Cancer Patients: a Multidisciplinary Approach Chairs: M.S. Aapro, CH J. Herrstedt, DK F.

Cachexia and Nutrition in Advanced Cancer Patients: a Multidisciplinary Approach Chairs: M.S. Aapro, CH J. Herrstedt, DK F. REPORT Cachexia and Nutrition in Advanced Cancer Patients: a Multidisciplinary Approach Chairs: M.S. Aapro, CH J. Herrstedt, DK F. Strasser, CH 13-14 March 2015 Barcelona, Spain The Conference Cachexia

More information

Laboratory Information for Public Health Excellence

Laboratory Information for Public Health Excellence Laboratory Information for Public Health Excellence Dale Nordenberg, MD LIPHE Initiative A Public-Private Partnership Eli Lilly, Fondation Merieux and RESAOLAB Partners, CDC and CDC Foundation, and GLI

More information

Metastatic Cancer: Questions and Answers. Key Points

Metastatic Cancer: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Metastatic Cancer: Questions

More information

www.rticc.org Red Temática de Investigación Cooperativa en Cáncer Barcelona, 1 de marzo del 2013

www.rticc.org Red Temática de Investigación Cooperativa en Cáncer Barcelona, 1 de marzo del 2013 1 st Meeting Epidemiology and Cancer Prevention Program RTICC Red Temática de Investigación Cooperativa en Cáncer www.rticc.org Barcelona, 1 de marzo del 2013 Programa reunión 10h. Introducción de la reunión.

More information

New Advances in Cancer Treatments. March 2015

New Advances in Cancer Treatments. March 2015 New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within

More information

Graduate Program Objective #1 Course Objectives

Graduate Program Objective #1 Course Objectives 1 Graduate Program Objective #1: Integrate nursing science and theory, biophysical, psychosocial, ethical, analytical, and organizational science as the foundation for the highest level of nursing practice.

More information

October 2, 2003 Don Genson, director Sloan Master s Programs, Eberly College of Science, Penn State dwg9@psu.edu

October 2, 2003 Don Genson, director Sloan Master s Programs, Eberly College of Science, Penn State dwg9@psu.edu Professional Master s Degree Programs at Penn State October 2, 2003 Don Genson, director Sloan Master s Programs, Eberly College of Science, Penn State dwg9@psu.edu 1 Three Very Different Programs Master

More information

FSH Society s 2014 Biennial FSHD Connect Meeting: Natural History Studies

FSH Society s 2014 Biennial FSHD Connect Meeting: Natural History Studies FSH Society s 2014 Biennial FSHD Connect Meeting: Natural History Studies Raymond A. Huml, MS, DVM, RAC Executive Director, Head, Global Biosimilars Business Development and Strategic Planning, Quintiles

More information

Daiichi Sankyo to Acquire Ambit Biosciences

Daiichi Sankyo to Acquire Ambit Biosciences For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please

More information

TRANSFORMING HEALTHCARE THROUGH CONTINUAL INNOVATION & REENGINEERING Institute for Advanced Application

TRANSFORMING HEALTHCARE THROUGH CONTINUAL INNOVATION & REENGINEERING Institute for Advanced Application TRANSFORMING HEALTHCARE THROUGH CONTINUAL INNOVATION & REENGINEERING Institute for Advanced Application REDEFINING HEALTHCARE A National Laboratory for Healthcare Transformation The Institute for Advanced

More information

Executive Part- Time Master Real Estate, Building & Energy. Jean Carassus & James Gilbert Director & academic head

Executive Part- Time Master Real Estate, Building & Energy. Jean Carassus & James Gilbert Director & academic head Executive Part- Time Master Real Estate, Building & Energy Jean Carassus & James Gilbert Director & academic head Summary 1/ Objectives, ambition, target 2/ An accredited post- graduate programme 3/ Active

More information

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of

More information

Collaboration, Big Data and the search for the Higgs Boson

Collaboration, Big Data and the search for the Higgs Boson Collaboration, Big Data and the search for the Higgs Boson Intel European Research and Innovation Conference October 23 rd 2012 Andrzej Nowak, CERN openlab Andrzej.Nowak@cern.ch The European Particle Physics

More information

Organic farming : key advantages to be encouraged

Organic farming : key advantages to be encouraged Stéphane Le Foll Minister of Agriculture, Agrifood and Forestry. Organic farming : key advantages to be encouraged «Organic farming and its products represent a dynamic and buoyant sector of the economy,

More information

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.

More information

2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant

2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant 2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant Guidelines & General Instructions for Application KEY DATES: Application Release Date: December 12, 2012 Application Deadline: February

More information

Department of Behavioral Sciences and Health Education

Department of Behavioral Sciences and Health Education ROLLINS SCHOOL OF PUBLIC HEALTH OF EMORY UNIVERSITY Core Competencies Upon graduation, a student with an MPH/MSPH should be able to: Use analytic reasoning and quantitative methods to address questions

More information

Project Scope. Background

Project Scope. Background Project Scope Project Name: Cancer Centre Collaboration Project Project Description: Project Leader: Robert Bull Project Code: Project End Date: May 2010 Version: 6 (Draft) Version Date: 19/01/10 Background

More information

Adaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) -

Adaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - Adaptimmune Reports Full Fiscal Year 2015 Financial Results - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - PHILADELPHIA, Pa. and OXFORD, United Kingdom., October 13, 2015 Adaptimmune

More information